AbbVie Inc (ABBV)vsPACS Group, Inc. (PACS)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
PACS
PACS Group, Inc.
$49.60
-1.20%
HEALTHCARE · Cap: $7.77B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1089% more annual revenue ($66.01B vs $5.55B). ABBV leads profitability with a 15.7% profit margin vs 4.8%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
PACS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 51.6% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
4.8% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : PACS
The primary concerns for PACS are P/E Ratio, Profit Margin, Altman Z-Score. Debt-to-equity of 2.83 is elevated, increasing financial risk. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a mature stock while PACS is a value play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.23 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 58/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across various sectors through innovative software and hardware systems. The company prioritizes research and development to leverage emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic collaborations and a solid market presence, PACS Group is well-positioned for sustainable growth, making it an attractive investment proposition for institutional investors seeking to participate in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?